Cancer Treatment Reviews
Volume 27, Issue 5 , Pages 261-273 , October 2001

Breast cancer prevention: present and future

References 

  1. Pisani P, Parkin DM, Bray F. Estimates of the world wide mortality from 25 cancers in 1990. Int J Cancer. 1999;83:18–29
  2. Easton D, Peto J. The contribution of inherited predisposition to cancer incidence. Cancer Survey. 1999;9:395–416
  3. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1 mutation carriers. Am J Hum Genet. 1995;56:265–271
  4. Feigelson HS, Henderson BE. Future possibilities in the prevention of breast cancer. Role of genetic variation in breast cancer prevention. Breast Cancer Res. 2000;2:277–282
  5. Cauley JA, Lucas FL, Kuller LH. Elevated serum estradiol and testosterone concentrations are associated with a high risk of breast cancer. Ann Intern Med. 1999;130:270–277
  6. Atkinson C, Warren R, Bingham SA. Mammographic patterns as a prediction biomarker of breast cancer risk: effect of tamoxifen. Cancer Epidemiol Biomark Prev. 1999;8:863–866
  7. Hankinson SE, Willett WC, Colditz GA. Circulating concentrations of insulin-like growth factor-1 and the risk of breast cancer. Lancet. 1998;9:1393–1396
  8. Boone CW, Kelloff G. Intraepithelial neoplasia, surrogate endpoint biomarkers, and cancer chemoprevention. J Cell Biochem. 1993;17:37–48
  9. Gail MH, Brinton LA, Byar DP. Projecting individualised probabilities of developing breast cancer for white female who are being examined annually. J Natl Cancer Inst. 1989;81:1879–1886
  10. Haden K, Santen R. Breast cancer prevention with tamoxifen. Lippincott's primary care practice. 2000;4:434–440
  11. Cuzick J, Wang DY, Bulbrook RD. The prevention of breast cancer. Lancet. 1986;i:83–86
  12. Cuzick J, Baum M. Tamoxifen and contralateral breast cancer (letter). Lancet. 1985;ii:
  13. Fornander T, Cedermark B, Mattson A. Adjuvant tamoxifen in early breast cancer. Occurrence of new primary cancers. Lancet. 1989;ii:1070–1073
  14. Fisher B, Costantino JP, Wickerham DL. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371–1388
  15. Lancet. 1998;351:1451–1467
  16. McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. Br Med. 1991;303:435–437
  17. Rutqvist LE, Mattson A. Cardiac and thromboembolic morbidity among postmenopausal women with early breast cancer in a randomised trial of adjuvant tamoxifen. J Natl Cancer Inst. 1993;85:1398–1406
  18. Day R, Ganz PA, Costantino JP. Health related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol. 1999;17:2659–2669
  19. Gail MH, Costantino JP, Bryant J. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 1999;91:1829–1846
  20. Veronesi U, Maisolmeuve P, Costa A. Prevention of breast cancer with tamoxifen: preliminary finding from the Italian randomised trial among hysterectomised women. Lancet. 1998;352:93–97
  21. Powles T, Eeles R, Ashley S. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 1998;352:98–101
  22. Cumming SR, Eckert S, Krueger KA. The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from MORE randomised trial. JAMA. 1999;281:2189–2197
  23. Fentiman IS, Wang DY, Allen DS. Bone density of normal women in relation to endogenous and exogenous estrogens. Br J Rheumatol. 1994;33:808–815
  24. Cauley JA, Lucas FL, Kuller LH. Bone mineral density and risk of breast cancer in older women. The study of osteoporotic fractures. JAMA. 1996;276:1404–1408
  25. Brzozowski AM, Pike AC, Dauter Z. Molecular basis of agonism and antagonism in estrogen receptor. Nature. 1997;389:753–758
  26. Walsh BW, Kuller LH, Wild RA. Effect of raloxifene on serum lipids and coagulation factor in healthy postmenopausal women. JAMA. 1998;279:1445–1451
  27. Delmas PD, Bjarnason NH, Mitalk BH. Effect of raloxifene on bone mineral density, serum cholesterol concentration, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337:1641–1647
  28. Ettinger B, Black DM, Mitalk BH. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA. 1999;282:637–645
  29. Osborne CK, Coronado E, Allred DC. Acquired tamoxifen resistance: correlation with reduced breast tumour levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst. 1991;83:1477–1482
  30. Gottardis MM, Jordan VC. Development of tamoxifen-stimulated growth of MCF-7 tumour in athymic mice after-long antiestrogen administration. Cancer Res. 1988;48:5183–5187
  31. Cuzick J. Chemoprevention of breast cancer with tamoxifen. In:  Hakama M,  Beral V,  Buiatti E,  Faivre J,  Parkin DM editor. Chemoprevention in Cancer Control. Lyon: IARC; 1996;p. 95–109
  32. Ziegler RG, Hoover RN, Pike MC. Migration pattern and breast cancer risk in Asian-American women. J Natl Cancer Inst. 1993;85:1819–1827
  33. Greenwald P. Role of dietary fat in the causation of breast cancer: point. Cancer Epidermiol Biomarkers Prev. 1999;8:3–7
  34. Hunter DJ. Role of dietary fat in the causation of breast cancer: counterpoint. Cancer Epidemiol. 1999;8:9–13
  35. Freedman L, Clifford C, Messina M. Analysis of dietary fat, calories, body weight and the development of mammary tumours in rats and mice: a review. Cancer Res. 1990;50:5710–5719
  36. Tannenbaum A. Genesis and growth of tumours III, effect of a high fat diet. Cancer Res. 1942;2:468–475
  37. Wu AH, Pike MC, Stram DO. Meta-analysis: dietary fat intake, serum estrogen levels, and the risk of breast cancer. J Natl Cancer Inst. 1999;91:529–534
  38. Willett WC. Dietary fat and breast cancer. Toxicol Sci. 1999;52:127–146
  39. Control Clin Trial. 1998;19:61–109
  40. Hunter DJ, Spiegelman D, Adami HO. Cohort studies of fat intake and the risk of breast cancer: a pooled analysis. New Engl J Med. 1996;334:356–361
  41. Howe GR, Hirohata T, Hislop TG. Dietary factors and risk of breast cancer: combined analysis of 12 case-control studies. J Natl Cancer Inst. 1990;82:561–569
  42. Greenwald P, Sherwood K, McDoland SS. Fat caloric intake and obesity: lifestyle risk factors for breast cancer. J Am Diet Assoc. 1997;97:S24–S30
  43. Holmes MD, Hunter DJ, Colditz GA. Association of dietary intake of fat and fatty acids with risk of breast cancer. JAMA. 1999;281:914–920
  44. Prentice RL, Sheppard L. Dietary fat and cancer: consistency of the epidemiologic data and disease prevention that may follow from a practical reduction in fat consumption. Cancer Causes Control. 1990;1:81–97
  45. Hunter DJ, Willett WC. Diet, body size and breast cancer. Epidemiol Rev. 1993;15:110–132
  46. Stoll BA. Adiposity as a risk determinant for postmenopausal breast cancer. Int J Obes Metab Disord. 2000;24:527–533
  47. Mc Tiernan A. Association between energy balance and body mass index and risk of breast carcinoma in women from diverse racial and ethnic background in the US. Cancer. 2000;88:1248–1255
  48. Del Giudice ME, Fantus IG, Ezzate S. Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat. 1998;47:110–120
  49. Frisch CM, Wyshak G, Albright NL. Lower prevalence of breast cancer and cancer of the reproductive system among former college athletes compared to non-athletes. Br J Cancer. 1985;52:88–91
  50. Longnecker MP. Alcoholic beverage consumption in relation to risk of breast cancer. Cancer Cause Control. 1994;5:73–82
  51. Lerman C, Narod S, Shulman K. BRCA1 testing in families with hereditary breast-ovarian cancer: a prospective study of patient decision making and outcomes. JAMA. 1996;275:1886–1892
  52. Eisen A, Weber BL. Prophylactic mastectomy – the price of fear. New J Engl Med. 1999;340:137–138
  53. Rebbeck TR, Levin AM, Eisen A. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 1999;91:1475–1479
  54. Boyle, P, Does alcohol consumption increase the risk of breast cancer?, Fentiman, I, S, Challenges in Breast Cancer, Oxford, Blackwell Science, 1999, 35, 41
  55. MacMahon BE, Trichopoulos D, Cole P. Cigarette smoking and urinary estrogens. N Engl J Med. 1982;307:1062–1065
  56. Khaw KT, Tazuke S, Barrett-Connor E. Cigarette smoking and the level of adrenal androgen in postmenopausal women. N Engl J Med. 1998;318:1705–1709
  57. Kaufman DW, Slone D, Rosenberg L. Cigarette smoking and age at natural menopause. Am J Public Health. 1980;70:420–422
  58. Fentiman IS. Future prospects for the prevention and cure of breast cancer (Review). Euro J Cancer. 2000;36:1085–1088
  59. Calle EE, Miracle-McMahill HL, Thun MJ. Cigarette smoking and risk of fatal breast cancer. Am J Epidemiol. 1994;139:1001–1007
  60. Zhang S, Hunter DJ, Forman MR. Dietary carotenoids and vitamin A, C, and E and risk of breast cancer. J Natl Cancer Inst. 1999;91:547–556
  61. Liu Y, Lee MO, Wang HG. Retinoic acid receptor β mediates the growth inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells. Mol Cell Biol. 1996;16:1138–1149
  62. Vink-van Wijngaarden T, Pols HA, Buurman CJ. Inhibition of insulin and insulin like growth factor-1-stimulated growth of human breast cancer by 1,25 dihydroxyvitamin D3 and the vitamin D3 analogue EB 1089. Eur J Cancer. 1996;32A:842–848
  63. Stoll BA. Western nutrition and the insulin resistance syndrome: a link to breast cancer. Eur J Clin Nutr. 1999;53:83–87
  64. Veronesi U, De Palo G, Marubini E. Randomised trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst. 1999;91:1847–1856
  65. Bonanni B, Ramazzotto F, Fanchi D. A randomised trial of fenretinide in HRT users using IGF-1 as a surrogate biomarker (abstract). Breast Cancer Res Treat. 2000;64:
  66. Lancet. 1997;350:1047–1059
  67. Ross RK, Paganini-Hill A, Wan PC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst. 2000;92:328–332
  68. Bergkvist L, Adami H-O, Persson I. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol. 1989;130:221–228
  69. Contraception. 1996;54:1S–106S
  70. Modan B, Chetrit A, Alfandary E. Increased risk of breast cancer after low-dose irradiation. Lancet. 1989;ii::629–631
  71. Mattsson A, Ruden BI, Hall . Radiation-induced breast cancer: long term follow up of radiation therapy for benign breast disease. J Natl Cancer Inst. 1993;85:1679–1685
  72. Ford D, Easton DF, Stratton M. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet. 1998;62:676–689
  73. Ford D, Easton DF, Bishop DT. Risk of cancer in BRCA1 mutation carriers. Lancet. 1994;343:992–995
  74. J Natl Cancer Inst. 1999;91:1310–1316
  75. Easton DF, Steele L, Field P. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet. 1998;61:120–128
  76. Lerman C, Seay J, Balshem A. Interest in genetic testing among first-degree relatives of breast cancer patients. Am J Med Genet. 1995;57:385–392
  77. Jacobsen PB, Valdimarsdottir HP, Brown KL. Decision-making about genetic testing among women at familial risk for breast cancer. Psychosom Med. 1997;59:459–466
  78. Meijers-Heijboer J, Verhoog L, Brekelmans C. Presymptomatic DNA testing and prophylactic surgery in families with BRCA1 and BRCA2 mutation. Lancet. 2000;355:2015–2020
  79. Klijn J GM, Janin N, Cortes-funes H. Should prophylactic surgery be used in women at risk of breast cancer?. Eur J Cancer. 1997;33:2149–2159
  80. Brunet JS, Ghadirian P, Rebeck TR. Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. J Natl Cancer Inst. 1998;90:716–765
  81. Jernström H, Lerman C, Ghadirian P. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet. 1999;354:1846–1850
  82. Verhoog LC, Brekelmans C TM, Seynaeve C. Survival and tumour characteristics of breast cancer patients with germline mutation of BRCA1. Lancet. 1998;351:316–321
  83. Fentiman IS. Prophylactic mastectomy – deliverance or delusion?. Br Med J. 1998;317:1402–1403
  84. Goldman LD, Goldwyn RM. Some anatomical considerations of subcutaneous mastectomy. Plast Reconstr Surg. 1973;51:502–508
  85. Pennisi VR, Capozzi A. Subcutaneous mastectomy data: final statistical analysis. Aesthetic Plast Surg. 1989;13:15–21
  86. Hartmann LC, Schaid DJ, Woods JE. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. New Engl Med. 1999;340:77–84
  87. Ziegler LD, Kroll SS. Primary breast cancer after prophylactic mastectomy. Am J Clin Oncol. 1991;14:451–454
  88. Willemsen HW, Kaas R, Peterse JH. Breast carcinoma in residual breast tissue after prophylactic bilateral subcutaneous mastectomy. Eur J Oncol. 1998;24:331–338
  89. Jameson MB, Roberts E, Nixon J. Metastatic breast cancer 42 years after bilateral subcutaneous mastectomies. J Clin Oncol. 1997;9:119–121
  90. Eldar S, Meguid MM, Beatty JD. Cancer of the breast after prophylactic subcutaneous mastectomy. Am J Surg. 1984;148:692–693
  91. Goodnight JE, Quagliana JM, Morton DL. Failure of subcutaneous mastectomy to prevent the development of breast cancer. J Surg Oncol. 1984;26:198–201
  92. Schrag D, Kuntz KM, Garber JE. Decision analysis effect of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutation. New Engl J Med. 1997;336:1465–1471
  93. Grann VR, Panageas KS, Whang W. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive and BRCA2-positive patients. J Clin Oncol. 1998;16:979–985
  94. Hartmann LC, Schaid D, Seller T. Bilateral prophylactic mastectomy in BRCA1/2 carriers. Proc Am Assoc Cancer Res. 2000;41:222–223
  95. Meijers-Heijboer H, Verhoog L, Brekelmans C. Prophylactic surgery in BRCA1/2 mutation carriers: predictive factors and follow-up. Am J Hum Genet. 1999;65:111
  96. Lynch HT, Lemon SJ, Durham C. A descriptive study of BRCA1 testing and reactions to disclosure of test result. Cancer. 1997;79:2219–2228
  97. Lynch HT, Watson P, Tinley S. An update on DNA-based BRCA1/BRCA2 genetic counselling in hereditary breast cancer. Cancer Genet Cytogenet. 1999;109:91–98
  98. Stefanek ME, Helzlsouer KJ, Wilcox PM. Prediction of and satisfaction with bilateral prophylactic mastectomy. Prev Med. 1995;24:412–419
  99. Bielanski TE. Does prophylactic mastectomy in women at high risk for breast cancer provide a psychological benefit?. J Family Prac. 2001;50:
  100. Frank TS, Manley SA, Olopade OI. Sequence analysis of BRCA1 and BRCA2: correlation of mutation with family history and ovarian cancer risk. J Clin Oncol. 1998;16:2417–2425
  101. Graham MD, Yelland A, Peacock . Bilateral carcinoma of the breast. Eur J Surg Oncol. 1993;19:259–264
  102. Robinson E, Rennett G, Rennett H. Survival of first and second primary breast cancer. Cancer. 1993;71:172–176
  103. Ford D, Easton DF, Bishop DT. Breast cancer linkage consortium and the risks of cancer in BRCA1 mutation carriers. Lancet. 1994;343:692–695
  104. MacMahon B, Feinleib M. Breast cancer in relation to nursing and menopausal history. J Natl Cancer Inst. 1960;24:733–753
  105. Llombart-Cussac , Bellet AM, Guillem-Porta V. Efficacy and safety of two doses of the selective estrogen receptor modulator (Serm) Ly 353381 in locally advanced or metastatic breast cancer (LAMBC): a randomised double blind phase 2 study (abstract). Proc Am Soc Clin Oncol. 2000;19:157a
  106. Harper-Wynne CL, Ross GM, Sack NP. Study of the biologic effect of the aromatase inhibitor letrozole in healthy postmenopausal women: rationale for prevention (abstract). Breast Cancer Res. 2000;64:47
  107. Nabholtz JM, Buzdar A, Pollak M. Anastrozole is superior to tamoxifen as a first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomised trial. J Clin Oncol. 2000;18:3758–3767
  108. Spicer DV, Pike MC. Future possibilities in the prevention of breast cancer: Luteinizing hormone-releasing hormone agonists. Breast Cancer Res. 2000;2:264–267
  109. Guzman RC, Yang J, Rajkumar L. Hormonal prevention of breast cancer: mimicking the protective effect of pregnancy. Proc Natl Acad USA. 1999;96:2520–2525
  110. Constantinou AI, Krygier AE, Methta RR. Genistein induces mutation of cultured human breast cancer cells and prevents tumour growth in nude mice. Am J Clin Nutrition. 1998;68:
  111. Key TJ, Sharp GB, Appleby PN. Soya food and breast cancer risk: a prospective study in Hiroshima and Nagasaki, Japan. Br J Cancer. 2000;81:1248–1256
  112. Cameron EE, Bachman KE, Myohanen S. Synergy of demethylation of histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nature. 1999;21:103–107
  113. Marks PA, Richon JM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation of apoptosis of transformed cells. J Natl Cancer Inst. 2000;92:1210–1216
  114. Nass SJ, Herman JG, Gabrielson E. Aberrant methylation of the estrogen receptor and E-cadherin 5′ CpG islands increases with malignant progression in human breast cancer. Cancer Res. 2000;60:4346–4348
  115. Ferguson AT, Lapidus RG, Baylin SB. Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res. 1995;55:2279–2283
  116. Sporn MB. Retinoids and demethylating agents – looking for partner. J Natl Cancer Inst. 2000;92:780–781
  117. Koki AT, Leahy KM, Masferre JL. Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Exp Opin Invest Drugs. 1999;8:1623–1638
  118. Nelson AR, Fingleton B, Rothenberg ML. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000;18:1135–1149
  119. Leveque J, Foucher F, Havouis R. Benefits of complete polyamine deprivation in hormone responsive and hormone resistant MCF-7 human breast adenocarcinoma in vivo. Anticancer Res. 2000;20:97–101
  120. Fregene TA, Kellogg CM, Pienta KJ. Microvessel quantification as a measure of angiogenic activity in benign breast tissue lesions: a marker for precancerous disease?. Int J Oncol. 1994;4:1999–2002
  121. Harris RE, Kasbari S, Farrar WB. Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep. 1999;6:71–73
  122. Kato S, Endoh H, Masuhiro Y. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 1995;270:1491–1494
  123. Gould MN. Prevention and therapy of mammary cancer by monoterpenes. J Cell Biochem Suppl. 1995;22:139–144
  124. Thompson HJ, Jiang C, Lu J. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res. 1997;57:267–271
  125. Fentiman IS. Future prospects for the prevention and cure of breast cancer. Eur J Cancer. 2000;36:1085–1088

PII: S0305-7372(01)90235-X

doi: 10.1053/ctrv.2001.0235

Cancer Treatment Reviews
Volume 27, Issue 5 , Pages 261-273 , October 2001

Article Tools